Non-Regulatory

April 20, 2016

Kallelse till årsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma fredagen den 20 maj 2016 klockan 16.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Read more

Non-Regulatory

April 13, 2016

Affibody AB enter into an Option Agreement regarding cancer-targeting molecules

Solna, Sweden, April 13, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Feasibility Study and Product Option Agreement with an unnamed partner.

Read more

Non-Regulatory

April 12, 2016

Affibody AB enter into an Option Agreement regarding IL-17-targeting molecules in Ophthalmology

Solna, Sweden, April 12, 2016 – Affibody AB (“Affibody”) today announced that the company has signed a Research License and Product Option Agreement with an unnamed partner.

Read more

Non-Regulatory

February 29, 2016

Kallelse till extra bolagsstämma

Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma måndagen den 14 mars 2016 kl 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Read more

Non-Regulatory

February 26, 2016

Year End Report 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

December 24, 2015

Affibody Licenses Albumod™ Half-life Extension Technology to MedImmune

Solna, Sweden, December 24, 2015. Affibody AB today announced that MedImmune has extended its Albumod™ platform licensing agreement

Read more

Non-Regulatory

December 1, 2015

Affibody receives clinical milestone from Daiichi Sankyo

Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo...

Read more

Non-Regulatory

November 20, 2015

Interim Report – January to September 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

August 21, 2015

Interim Report – January to June 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more